ATE520712T1 - Antiangiogene verbindungen - Google Patents

Antiangiogene verbindungen

Info

Publication number
ATE520712T1
ATE520712T1 AT07827123T AT07827123T ATE520712T1 AT E520712 T1 ATE520712 T1 AT E520712T1 AT 07827123 T AT07827123 T AT 07827123T AT 07827123 T AT07827123 T AT 07827123T AT E520712 T1 ATE520712 T1 AT E520712T1
Authority
AT
Austria
Prior art keywords
compounds
antiangiogenic compounds
targeting
antibody
linked
Prior art date
Application number
AT07827123T
Other languages
English (en)
Inventor
Curt Bradshaw
Abhijit Bhat
Jing-Yu Lai
Venkata Doppalapudi
Dingguo Liu
Original Assignee
Covx Technologies Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Covx Technologies Ireland Ltd filed Critical Covx Technologies Ireland Ltd
Application granted granted Critical
Publication of ATE520712T1 publication Critical patent/ATE520712T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/515—Angiogenesic factors; Angiogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT07827123T 2006-11-10 2007-11-12 Antiangiogene verbindungen ATE520712T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US86536006P 2006-11-10 2006-11-10
US93983007P 2007-05-23 2007-05-23
US94532907P 2007-06-20 2007-06-20
PCT/IE2007/000110 WO2008056346A2 (en) 2006-11-10 2007-11-12 Anti-angiogenic compounds

Publications (1)

Publication Number Publication Date
ATE520712T1 true ATE520712T1 (de) 2011-09-15

Family

ID=39364902

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07827123T ATE520712T1 (de) 2006-11-10 2007-11-12 Antiangiogene verbindungen

Country Status (18)

Country Link
US (3) US8288349B2 (de)
EP (2) EP2089425B1 (de)
JP (2) JP4897050B2 (de)
KR (2) KR20120043028A (de)
CN (1) CN101611053B (de)
AT (1) ATE520712T1 (de)
AU (1) AU2007318912B2 (de)
BR (1) BRPI0718591A2 (de)
CA (1) CA2669207A1 (de)
DK (1) DK2089425T3 (de)
IL (1) IL198581A (de)
MX (1) MX2009005045A (de)
MY (1) MY146985A (de)
NO (1) NO20092203L (de)
NZ (1) NZ576751A (de)
PL (1) PL2089425T3 (de)
PT (1) PT2089425E (de)
WO (1) WO2008056346A2 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY146985A (en) * 2006-11-10 2012-10-15 Covx Technologies Ireland Ltd Anti-angiogenic compounds
US20090098130A1 (en) * 2007-01-05 2009-04-16 Bradshaw Curt W Glucagon-like protein-1 receptor (glp-1r) agonist compounds
US8293714B2 (en) 2008-05-05 2012-10-23 Covx Technology Ireland, Ltd. Anti-angiogenic compounds
WO2010036930A1 (en) * 2008-09-26 2010-04-01 Javad Parvizi Methods and kits for detecting joint infection
WO2012007896A1 (en) * 2010-07-12 2012-01-19 Covx Technologies Ireland, Ltd. Multifunctional antibody conjugates
RU2013118441A (ru) 2010-11-05 2014-12-10 КовЭкс Текнолоджиз Айэлэнд Лимитед Антидиабетические соединения
EP2726088B1 (de) 2011-06-29 2019-01-02 Amgen Inc. Prädiktiver überlebensbiomarker bei der behandlung von nierenzellkarzinomen
RU2014124989A (ru) * 2011-12-20 2016-02-10 Пфайзер Инк. Улучшенные способы получения пептидных конъюгатов и линкеров
EP2802355B1 (de) * 2012-01-09 2018-09-05 CovX Technologies Ireland Limited Mutante antikörper und konjugation davon
JP6219923B2 (ja) 2012-03-28 2017-10-25 アムジェン インコーポレイテッド Ｄｒ５受容体アゴニストの組み合わせ
CN111875670A (zh) 2013-06-12 2020-11-03 法瑞斯生物技术有限公司 对天然cxcr4具有拮抗活性的肽
WO2015014376A1 (en) * 2013-07-31 2015-02-05 Biontech Ag Diagnosis and therapy of cancer involving cancer stem cells
EA201690780A1 (ru) * 2013-10-15 2016-08-31 Сиэтл Дженетикс, Инк. Пегилированные лекарственные средства-линкеры для улучшенной фармакокинетики конъюгатов лиганд-лекарственное средство
US20190004048A1 (en) 2015-06-26 2019-01-03 Amgen Inc. Biomarker of Survival in the Treatment of Renal Cell Carcinoma with a VEGFR Inhibitor and an Ang2 Inhibitor
US11793880B2 (en) 2015-12-04 2023-10-24 Seagen Inc. Conjugates of quaternized tubulysin compounds
AU2016363013B2 (en) 2015-12-04 2022-03-10 Seagen Inc. Conjugates of quaternized tubulysin compounds
EA201892040A1 (ru) 2016-03-25 2019-04-30 Сиэтл Дженетикс, Инк. Способ получения пегилированных соединений лекарственный препарат - линкер и их промежуточных соединений
CN110637027B (zh) 2017-02-08 2024-08-30 百时美施贵宝公司 包含药代动力学增强子的修饰的松弛素多肽及其用途
CA3056134A1 (en) 2017-03-24 2018-09-27 Seattle Genetics, Inc. Process for the preparation of glucuronide drug-linkers and intermediates thereof
EP3617235A4 (de) 2017-04-28 2020-12-16 Ajinomoto Co., Inc. Verbindung mit einer substanz mit affinität zu löslichem protein, spaltbarem teil und reaktiver gruppe oder salz davon

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3719667A (en) 1970-08-24 1973-03-06 Lilly Co Eli Epimerization of 6-acylamido and 6-imido penicillin sulfoxide esters
US3840556A (en) 1971-05-28 1974-10-08 Lilly Co Eli Penicillin conversion by halogen electrophiles and anti-bacterials derived thereby
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US5216132A (en) 1990-01-12 1993-06-01 Protein Design Labs, Inc. Soluble t-cell antigen receptor chimeric antigens
DK0527798T3 (da) 1990-04-06 1997-12-15 Jolla Cancer Res Found Fremgangsmåde og sammensætning til behandling af thrombose
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US6080840A (en) 1992-01-17 2000-06-27 Slanetz; Alfred E. Soluble T cell receptors
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
US5981478A (en) 1993-11-24 1999-11-09 La Jolla Cancer Research Foundation Integrin-binding peptides
US5733757A (en) 1995-12-15 1998-03-31 The Scripps Research Institute Aldolase catalytic antibody
US5739277A (en) 1995-04-14 1998-04-14 Genentech Inc. Altered polypeptides with increased half-life
DE19544393A1 (de) 1995-11-15 1997-05-22 Hoechst Schering Agrevo Gmbh Synergistische herbizide Mischungen
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
US6326176B1 (en) 1997-12-18 2001-12-04 The Scripps Research Institute Aldol condensations by catalytic antibodies
JP2003516121A (ja) 1999-09-27 2003-05-13 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 不可逆的に結合するエンジニアリング抗体
US6294374B1 (en) 1999-10-08 2001-09-25 The Scripps Research Institute Use of catalytic antibodies for synthesizing epothilone
DE60237282D1 (de) 2001-06-28 2010-09-23 Domantis Ltd Doppelspezifischer ligand und dessen verwendung
US20030045477A1 (en) 2001-07-26 2003-03-06 Fortuna Haviv Peptides having antiangiogenic activity
US7138370B2 (en) 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
US7205275B2 (en) * 2001-10-11 2007-04-17 Amgen Inc. Methods of treatment using specific binding agents of human angiopoietin-2
EP2428226A1 (de) * 2001-10-22 2012-03-14 The Scripps Research Institute Verbindungen zum Targeting von Antikörpern
US6737524B2 (en) * 2002-03-25 2004-05-18 Paul K. Smith Activated polyethylene glycol compounds
DK1517921T3 (da) 2002-06-28 2006-10-09 Domantis Ltd Immunglobulin-enkeltvariable antigen-bindende domæner og dobbeltspecifikke konstruktioner deraf
CA2511910A1 (en) 2002-12-27 2004-07-15 Domantis Limited Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
US8143380B2 (en) 2004-07-08 2012-03-27 Amgen Inc. Therapeutic peptides
JP5017116B2 (ja) 2004-09-24 2012-09-05 アムジエン・インコーポレーテツド 修飾Ｆｃ分子
MY146985A (en) * 2006-11-10 2012-10-15 Covx Technologies Ireland Ltd Anti-angiogenic compounds

Also Published As

Publication number Publication date
EP2089425B1 (de) 2011-08-17
CN101611053A (zh) 2009-12-23
AU2007318912A1 (en) 2008-05-15
WO2008056346A2 (en) 2008-05-15
US8288349B2 (en) 2012-10-16
MY146985A (en) 2012-10-15
EP2089425A2 (de) 2009-08-19
EP2368908A3 (de) 2011-10-12
AU2007318912B2 (en) 2011-03-03
WO2008056346B1 (en) 2008-12-04
KR20090090331A (ko) 2009-08-25
DK2089425T3 (da) 2011-10-10
IL198581A0 (en) 2011-08-01
EP2368908A2 (de) 2011-09-28
BRPI0718591A2 (pt) 2013-12-03
MX2009005045A (es) 2009-11-10
CN101611053B (zh) 2015-06-03
KR20120043028A (ko) 2012-05-03
IL198581A (en) 2015-10-29
JP4897050B2 (ja) 2012-03-14
WO2008056346A3 (en) 2008-10-23
JP2012121886A (ja) 2012-06-28
JP2010509315A (ja) 2010-03-25
US20080166364A1 (en) 2008-07-10
US8912148B2 (en) 2014-12-16
PL2089425T3 (pl) 2012-02-29
NZ576751A (en) 2011-10-28
US20150057431A1 (en) 2015-02-26
PT2089425E (pt) 2011-10-17
US20120301431A1 (en) 2012-11-29
NO20092203L (no) 2009-08-10
KR101309948B1 (ko) 2013-09-23
CA2669207A1 (en) 2008-05-15

Similar Documents

Publication Publication Date Title
ATE520712T1 (de) Antiangiogene verbindungen
WO2006094269A3 (en) Anti-angiogenic compounds
DOP2012000038A (es) Conjugados de dímeros de pirrolo [1,4] benzodiazepina como agentes anticancerosos
CY1118349T1 (el) Παραγοντες συνδεσης me cd19 και χρησεις αυτων
MX2009007146A (es) Conjugados porcion del factor ix-polimero que tienen ligadura que se puede liberar.
CY1119077T1 (el) Παραγωγα πυραζολυλαμινοπυριδινης χρησιμα ως αναστολεις κινασων
EA201000903A1 (ru) Антитела к pcrv-антигену pseudomonas aeruginosa
CL2007003854A1 (es) Compuestos derivados de ciclopamina; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto, util en el tratamiento de desordenes mediados por la via de hedgehog, como cancer.
HN2006000668A (es) Compuestos de quinolina heteroaromaticos
EA201200486A1 (ru) Лечение онкологических заболеваний
CR20140316A (es) Derivados de indol como antagonistas receptores de s1p1 (divisional 10922)
SE0203713D0 (sv) Novel compounds
WO2009051670A3 (en) Oxylipin compounds for the treatment of ophthalmic conditions
HN2008001191A (es) Compuestos de biciclolactama sustituida
EA201270049A1 (ru) Дизамещенные фталазиновые антагонисты пути hedgehog
GB2466912A (en) Compositions and methods for treating lysosomal disorders
MX2010002732A (es) Inhibidores de f1f0-atpasa y metodos relacionados.
WO2007138282A3 (en) Bi-aryl or aryl-heteroaryl substituted indoles
MX2007011847A (es) Derivados de pirimidindiona como antagonistas del receptor de procineticina 2.
EA200971068A1 (ru) Триазолиламинопиримидиновые соединения
EA201170699A1 (ru) Тетразамещенные пиридазины в качестве антагонистов пути hedgehog
EA201170640A1 (ru) Дизамещенные фталазины-антагонисты сигнального пути hedgehog
NO20074047L (no) Ny fremgangsmate for fremstilling av substituerte indoler
ATE520651T1 (de) Substituierte phenylmethylbicyclocarbonsäureamidverbindungen
EA201270818A1 (ru) 6-(1-МЕТИЛ-1H-ПИРАЗОЛ-4-ИЛ)-3-(2-МЕТИЛ-2H-ИНДАЗОЛ-5-ИЛТИО)-[1,2,4]ТРИАЗОЛ-[43-b]ПИРИДАЗИН В КАЧЕСТВЕ ИНГИБИТОРА c-МЕТ

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 2089425

Country of ref document: EP